Global Hemodynamic Monitoring Market valued at $1.04 billion in 2021, is expected to witness a CAGR of 6% by 2026 - Growing Cases of Cardiovascular, COPD and Respiratory Diseases

Uncontrolled perturbations in circulatory functions during surgery can lead to tissue hypoxia, thus resulting in perioperative morbidity and mortality. Hemodynamic monitoring provides information about the adequacy of a patient's circulation, perfusion and oxygenation of the tissues and organ systems thus delivering safe anesthetic care.

Technological Advancements in Hemodynamic Monitoring Systems to trigger its Global Market Demand

Consistent innovations and advancements in patient care have enabled to develop an efficient hemodynamic monitoring system featuring non-invasive technology and expanded parameters such as continuous BP measurements, measurement of cardiac output by pulse contour method, among others. Leading market players are focusing on investing in research activities for new product developments and expanding their geographic reach to strengthen their position in the global market.

Some of the recent technological advancements are listed below as:
• In July 2022, Retia Medical received Series B funding of $15 million led by Fresenius Medical Care Ventures to expand its commercial team and accelerate the development and commercialization of its Argos Hemodynamic Monitor.
• In February 2022, Caretaker Medical received the US Food and Drug Administration (FDA) clearance to add four new parameters on its next-generation VitalStream wireless 'beat-by-beat' blood pressure and hemodynamic monitoring platform, to include stroke volume, cardiac output, left ventricular ejection time, and heart rate variability.

Rising Cases of Cardiovascular Diseases to boost the Adoption of Hemodynamic Monitoring Market

Advanced hemodynamic monitoring methods have the ability to enhance the monitoring of cardiac patients during post-operative care and anaesthesia thus providing precise and repeatable measurements to detect hemodynamic abnormalities and their causes. Cardiovascular diseases are one of the major causes of death across the world.

Coronary heart disease, cerebrovascular disease, rheumatic heart disease and other diseases are among the group of heart and blood vessel disorders known as CVDs.
• According to WHO, 32% of all deaths across the world i.e., 17.9 million people die due to CVD every year.
• As per CDC,
o 659,000 people in United States die from heart disease every year; heart diseases costs $363 billion each year in US which includes cost of medicines and healthcare services.
o Coronary heart disease alone killed 360,900 people in 2019 in USA and over 18.2 million adults suffering from coronary artery disease live in USA.
o 805,000 people suffer from heart attack in USA every year of which 605,000 are a first heart attack while 200,000 happen to people already had a heart attack.
• According to European Heart Network, CVDs account for over 3.9 million deaths every year in the European region, out of which over 1.8 million deaths occur in the European Union (EU).

Furthermore, growing aging population are prone to heart defects due to progressive deterioration in the structure and function of the heart, largely contributes to the high burden of CVDs; thereby triggering the increased adoption of hemodynamic monitoring systems.

Competitive Landscape Analysis: Hemodynamic Monitoring Market

The global hemodynamic monitoring market is marked by the presence of established market players such as Edwards Lifesciences Corporation (US); Getinge AB (Sweden); LiDCO Group (UK); Koninklijke Philips N.V. (Netherlands); ICU Medical (US); and others.

Get Detailed Insights on Hemodynamic Monitoring Market with a Sample Report @ https://meditechinsights.com/hemodynamic-monitoring-market/

Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/
https://www.linkedin.com/company/medi-tech-insights/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.